热门出版物 - 学术资源搜索

h5 指数:97
h5 中位数:150

h5 指数是指在过去整整 5 年中所发表文章的 h 指数。h 指在 2018-2022 年间发表的 h 篇文章每篇至少都被引用过 h 次的最大值。隐藏

出版物的 h5 中位数，是指出版物的 h5 指数所涵盖的所有文章获得的引用次数的中位值。隐藏

#17 Oncology

标题/作者	引用次数	年份
Commensal microbiota associated with anti-PD-1 efficacy in metastatic melanoma patients V Matson, J Fessler, R Bao, T Chongsuwat, Y Zha, ML Alegre, J Luke, ... JOURNAL FOR IMMUNOTHERAPY OF CANCER 5	1559	2017
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group I Puzanov, A Diab, K Abdallah, CO Bingham, C Brogdon, R Dadu, ... Journal for ImmunoTherapy of Cancer 5 (1), 1-28	1180	2017
Cytokine release syndrome A Shimabukuro-Vornhagen, P Gödel, M Subklewe, HJ Stemmler, ... Journal for ImmunoTherapy of Cancer 6 (1), 1-14	968	2018
Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade S Wei, J Levine, A Cogdill, Y Zhao, NA Anang, M Andrews, P Sharma, ... JOURNAL FOR IMMUNOTHERAPY OF CANCER 5	843	2017
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations J Gong, A Chehrazi-Raffle, S Reddi, R Salgia Journal for ImmunoTherapy of Cancer 6 (1), 1-18	805	2018
Identification of unique neoantigen qualities in long-term pancreatic cancer survivors V Balachandran, M Luksza, JN Zhao, V Makarov, JA Moral, R Remark, ... JOURNAL FOR IMMUNOTHERAPY OF CANCER 5	647	2017
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy MA Cannarile, M Weisser, W Jacob, AM Jegg, CH Ries, D Rüttinger Journal for ImmunoTherapy of Cancer 5 (1), 1-13	627	2017
Gene expression markers of Tumor Infiltrating Leukocytes P Danaher, S Warren, L Dennis, L D’Amico, A White, ML Disis, MA Geller, ... Journal for ImmunoTherapy of Cancer 5 (1), 1-15	408	2017
The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors AA Davis, VG Patel Journal for ImmunoTherapy of Cancer 7 (1), 1-8	395	2019
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors S Das, DB Johnson Journal for ImmunoTherapy of Cancer 7 (1), 1-11	355	2019
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death L Galluzzi, I Vitale, S Warren, S Adjemian, P Agostinis, AB Martinez, ... Journal for ImmunoTherapy of Cancer 8 (1), e000337	319	2020
Targeting adenosine for cancer immunotherapy RD Leone, LA Emens Journal for ImmunoTherapy of Cancer 6 (1), 1-9	293	2018
Combination immunotherapy: a road map PA Ott, FS Hodi, HL Kaufman, JM Wigginton, JD Wolchok Journal for ImmunoTherapy of Cancer 5 (1), 1-15	291	2017
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) EEW Cohen, RB Bell, CB Bifulco, B Burtness, ML Gillison, KJ Harrington, ... Journal for ImmunoTherapy of Cancer 7 (1), 1-31	283	2019
High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors S Maleki Vareki Journal for ImmunoTherapy of Cancer 6 (1), 1-5	279	2018
Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC) YK Chae, A Arya, W Iams, MR Cruz, S Chandra, J Choi, F Giles Journal for ImmunoTherapy of Cancer 6 (1), 1-27	268	2018
Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after≥ 1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial HL Kaufman, JS Russell, O Hamid, S Bhatia, P Terheyden, SP D’Angelo, ... Journal for ImmunoTherapy of Cancer 6 (1), 1-7	262	2018
Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment SM Steggerda, MK Bennett, J Chen, E Emberley, T Huang, JR Janes, ... Journal for ImmunoTherapy of Cancer 5 (1), 1-18	234	2017
Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy AJ Giles, MKND Hutchinson, HM Sonnemann, J Jung, PE Fecci, ... Journal for ImmunoTherapy of Cancer 6 (1), 1-13	219	2018
Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA) P Danaher, S Warren, R Lu, J Samayoa, A Sullivan, I Pekker, B Wallden, ... Journal for ImmunoTherapy of Cancer 6 (1), 1-17	203	2018

1 - 20

计算机程序会自动估算并确定日期和引用次数。